Drug Trial Radar · NCT04347239
Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
Last checked: Nov 19, 2026Latest source record: Oct 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
484
Actual
Start
Apr 16, 2020
Primary completion
Oct 24, 2021
Study completion Jun 15, 2022
Sponsor
- Lead sponsor
- CytoDyn, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 15, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.
Conditions
- Coronavirus Disease 2019
Interventions
PlaceboDrug
Placebo
Leronlimab (700mg)Drug
Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause Mortality at Day 28Time frame: Mortality at day 28 (Visit 2, start of treatment = day 0)
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Advanced Cardiovascular, LLC
Alexander City, Alabama
St. Jude Medical Center
Fullerton, California
UCLA
Los Angeles, California
James A. Haley Veterans' Hospital
Tampa, Florida
Center for Advanced Research & Education (CARE)
Gainesville, Georgia
Beth Israel Deaconess Medical Center
Boston, Massachusetts
St. Barnabas
Livingston, New Jersey
Atlantic Health System Hospital
Morristown, New Jersey
Holy Name Medical Center
Teaneck, New Jersey
New York Community Hospital of Brooklyn
Brooklyn, New York
Montefiore Medical Center
The Bronx, New York
Novant Health
Winston-Salem, North Carolina
Ohio Health
Columbus, Ohio
Good Samaritan Hospital Corvallis
Corvallis, Oregon
Oregon Health and Sciences University
Portland, Oregon
Baylor Scott & White Research Institute
Dallas, Texas
Baylor College of Medicine
Houston, Texas
University of Texas
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.